Imitrex Drug Classification
Imitrex (sumatriptan) is a selective 5-HT₁B/1D receptor agonist, commonly known as a "triptan," used for acute migraine treatment. 1, 2
Pharmacologic Class Details
Sumatriptan belongs to the serotonin-1B and serotonin-1D receptor agonist class (triptans), which are migraine-specific medications that work by selectively targeting 5-hydroxytryptamine (5-HT) receptors 3, 2. The FDA drug label specifically describes it as containing "sumatriptan (as the succinate), a selective 5-hydroxytryptamine1 receptor subtype agonist" 2.
Mechanism and Clinical Context
The triptan class represents a major advancement from older ergotamine derivatives, which are nonselective 5-HT receptor agonists 1. Triptans are specifically designed as 5-HT₁ receptor-specific agonists, distinguishing them from the broader, less selective action of ergot alkaloids 1.
Available Formulations
Sumatriptan is unique among triptans in offering multiple routes of administration 1:
- Subcutaneous injection (6 mg) - reaches peak concentration fastest at ~15 minutes
- Oral tablets (25 mg, 50 mg, 100 mg)
- Intranasal spray (5-10 mg)
- Rectal suppository (25 mg)
The subcutaneous formulation achieves the most rapid onset and highest efficacy (70-82% effective), making it particularly valuable when speed of relief is critical 1, 4.
Clinical Classification Context
Triptans are reserved for moderate to severe migraines or mild to moderate migraines unresponsive to analgesics or NSAIDs 1. They are considered migraine-specific abortive medications, not preventive agents 2. The 2025 ACP guidelines classify sumatriptan alongside other triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) as "serotonin-1B and serotonin-1D receptor agonists" for acute episodic migraine treatment 3.
Important Contraindications
As a class, triptans are contraindicated in patients with ischemic vascular conditions, vasospastic coronary disease, uncontrolled hypertension, or significant cardiovascular disease 1. They should not be used within 24 hours of ergotamine derivatives or other triptans 1, 2.